Salarius Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under ticker SLRX. The company has historically been headquartered in Houston, Texas, and has operated as a clinical-stage oncology developer focused on therapies that address dysregulated gene expression in hematologic malignancies and solid tumors. From an international equity perspective, Salarius fits the profile of a small-cap biotech whose valuation is primarily driven by clinical milestones, regulatory progress, capital markets access, and strategic transactions rather than commercial revenue. Its core business has centered on two principal drug candidates built around protein inhibition and protein degradation. The best-known program is seclidemstat (SP-2577), an orally available LSD1 inhibitor that has been investigated in oncology settings with limited treatment options, including Ewing sarcoma and certain blood cancers. The second major asset is SP-3164, a targeted protein degrader designed to address difficult-to-drug cancer-related targets and to participate in the emerging targeted protein degradation field. Together, these programs positioned Salarius in a specialized segment of cancer drug development where scientific differentiation, intellectual property, and early clinical data are critical competitive variables. Salarius does not compete with large diversified pharmaceutical companies on scale; instead, it competes within the highly competitive universe of development-stage biotech companies. That means its competitive position has depended on the quality of its science, the strength of its academic and clinical relationships, and its ability to raise capital through equity markets or strategic financing. Its geographic footprint has been largely U.S.-centric, with development, regulatory and clinical activities concentrated in the United States and supported by collaborations with research and medical institutions. Recent developments have been especially material. In 2025, the company had to address NASDAQ listing compliance issues tied to both minimum bid price and stockholders’ equity requirements, culminating in a 1-for-15 reverse stock split in August 2025 to help restore compliance with the exchange’s minimum price standard. Separately, Salarius announced a definitive merger agreement with Decoy Therapeutics, a transaction intended to reshape the combined company’s platform and expand its pipeline into peptide conjugate therapeutics and applications in respiratory infectious diseases and gastrointestinal oncology. For investors in France, Belgium and Switzerland, this makes Salarius a high-risk, event-driven biotech name to monitor through SEC filings, clinical updates, financing news, and merger completion milestones. The company trades on the NASDAQ in the United States, and its profile remains that of a development-stage oncology biotech rather than a commercial-stage pharma business.